Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

(PEG)-BHD1028

Next Previous
X
Search
Drug Profile

(PEG)-BHD1028

Alternative Names: (PEG) BHD1028; BHD-1028; ECN 0424; ECN 0827; ECN 1028; ECN 3003; Pegylated-BHD1028

Latest Information Update: 12 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EncuraGen
  • Class Antihyperglycaemics; Eye disorder therapies; Hepatoprotectants; Obesity therapies; Peptides
  • Mechanism of Action Adiponectin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Dry eyes
  • Phase I Type 2 diabetes mellitus
  • Preclinical Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Obesity

Most Recent Events

  • 01 Feb 2024 Preclinical trials in Non-alcoholic steatohepatitis in USA (unspecified route) prior to February 2024
  • 01 Feb 2024 EncuraGen completes a phase I trial in Type 2 diabetes mellitus
  • 01 Feb 2024 Preclinical trials in Non-alcoholic fatty liver disease in South Korea (unspecified route) before September 2024 (Encuragen pipeline, September 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top